GBM (glioblastoma multiforme) is the most common and aggressive brain tumor. To date, treatment options for glioblastoma recurrence are lacking. Recently, REGOMA trial showed the superiority of regorafenib to lomustine in patients with first glioblastoma recurrence. We report an excellent response to three months treatment with regorafenib, in a patient who presented a rapid progression after the end of post operative radio-chemotherapy and after only one cycle of adjuvant TMZ (Temozolomide).

Regorafenib in glioblastoma recurrence: A case report / Detti B.; Scoccianti S.; Lucidi S.; Maragna V.; Teriaca M.A.; Ganovelli M.; Desideri I.; Lorenzetti V.; Scoccimarro E.; Greto D.; Livi L.. - In: CANCER TREATMENT AND RESEARCH COMMUNICATIONS. - ISSN 2468-2942. - ELETTRONICO. - 26:(2021), pp. 0-0. [10.1016/j.ctarc.2020.100263]

Regorafenib in glioblastoma recurrence: A case report

Detti B.;Scoccianti S.;Lucidi S.;Maragna V.;Teriaca M. A.;Ganovelli M.;Desideri I.;Lorenzetti V.;Scoccimarro E.;Greto D.;Livi L.
2021

Abstract

GBM (glioblastoma multiforme) is the most common and aggressive brain tumor. To date, treatment options for glioblastoma recurrence are lacking. Recently, REGOMA trial showed the superiority of regorafenib to lomustine in patients with first glioblastoma recurrence. We report an excellent response to three months treatment with regorafenib, in a patient who presented a rapid progression after the end of post operative radio-chemotherapy and after only one cycle of adjuvant TMZ (Temozolomide).
2021
26
0
0
Detti B.; Scoccianti S.; Lucidi S.; Maragna V.; Teriaca M.A.; Ganovelli M.; Desideri I.; Lorenzetti V.; Scoccimarro E.; Greto D.; Livi L.
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S2468294220300988-main.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 5.18 MB
Formato Adobe PDF
5.18 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1282641
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? ND
social impact